N4 Pharma plc Financials

Market Capitalization £3.1 Million as of July 1, 2025

Valuations Metrics as of May. 5, 2024

Trailing PE	-153.85
Forward PE
Price to Sales TTM	£1066.59
Price to Book MRQ	£193.75
Enterprise to Revenue	574.47
Enterprise to EBITDA	-0.84

Financial Reports as of Dec. 31, 2023

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2023-12-31
Profit Margin	0.00%
Operating Margin	-35338.49%
Return on Assets TTM	-48.51%
Return on Equity TTM	-77.81%

Income Statement

Revenue TTM	£1,953
Revenue per Share TTM	£0.00
Quarterly Revenue Growth	%
Gross Profit TTM	£0
EBITDA	£0
Net Income to Common TTM	£-1,269,331
Diluted EPS TTM	£-0.01
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	£1,027,112
Total Cash per Share MRQ	£0.00
Total Debt MRQ	£
Total Debt to Equity MRQ	0.00
Current Ratio MRQ	14.86
Book Value per Share MRQ	£0.00

Cash Flow

Operating Cash Flow TTM	£-1,209,098
Levered Free Cash Flow TTM	£-767,896

N4P Stock Info as of May. 5, 2024

Stock Statistics

Shares Outstanding	268,780,000
Float Shares	208,651,497
Avg 10 Volume	1,483,147
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	22.28%
% Held by Institutions	0.00%

Stock Price Summary

Beta	-0.03
Fifty Two Week Low	£0.01
Fifty Two Week High	£2.16
Fifty Two Week Change	-137.50%
Day 50 MA	£0.75
Day 200 MA	£1.01

Dividends and Splits

Forward Annual Dividend Rate	£72.00
Forward Annual Dividend Yield	9000.00%
Trailing Annual Dividend Rate	£0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date	1997-05-19
Last Split Factor
Last Split Date	2017-05-03